The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Johnson & Johnson‘s (NYSE:JNJ) Biosense Webster subsidiary said it won pre-market approval from the FDA for its ThermoCool SmartTouch force-sensing ablation catheter, making it the 1st such device to hit the U.S. market.
Geneva-based Endosense’s proprietary contact force technology improves efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, according to new study data released last week at the annual Heart Rhythm Society meeting.
EndoSense said it’s logged the 1st use of its TactiCath Quartz contact-force sensing ablation catheter in a new arm of its Toccastar trial of the device.
The TactiCath Quartz uses a force sensor to indicate whether the ablation catheter, used to treat cardiac arrhythmias, is in contact with the portion of the heart muscle to be ablated.
The TactiCath Quartz device won CE Mark approval in the European Union last year.*
Cather ablation technology maker Endosense announced the close of a $40.3 million Series C funding round this week, supported by new and existing investors in the Geneva-based company.
Funding was led by new investor NGN Capital but drew "large participation" from all existing investors as well as from employees, according to a press release.
Jan Keltjens is betting Endosense and its TactiCath technology can compete with 1 of the largest players in cardiac ablation: Johnson & Johnson‘s (NYSE:JNJ) BioSense Webster division.
Patients with a common heart rhythm disorder who received treatment with cardiac ablation were arrhythmia-free longer than patients taking drugs, suggesting that ablation should be a 1st-order approach to managing an erratic heart beat, according to a new study.
Unveiled at this year’s Heart Rhythm Society in Boston, the study found that patients with paroxysmal atrial fibrillation who received ablation therapy were 20% less likely to see a recurrence than patients taking anti-arrhythmic medication.
Bob Langer, MIT professor and bioengineering hot-shot, was chosen to recieve the 2011 Alpert Prize for his advancements in drug delivery and tissue engineering.
GENEVA–(BUSINESS WIRE)–Endosense Names Jan Keltjens President and Chief Executive Officer
Endosense and GE Healthcare have inked a deal to jointly develop an all-in-one catheter ablation system for the treatment of cardiac arrhythmias.
Endosense is merging tip-to-tissue data from its force-sensing catheter with GE’s CardioLab electrophysiology recording and Innova imaging platforms.
